Improve attention memory and walking
- Trial ID
- NCT05968703
- Official Title
- Neurostimulation of the Nucleus Basalis of Meynert for the Cognitive-Motor Syndrome in Parkinson's Disease
- Goal
- Improve attention memory and walking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Helen M. Bronte-Stewart
- Study Type
- INTERVENTIONAL
- Enrollment
- 10 participants
- Conditions
- Parkinson's Disease, Mild Cognitive Impairment
- Interventions
- Combined STN+NBM DBS
Plain-Language Summary
The goal is to treat the cognitive-motor syndrome in Parkinson's, where trouble with attention, memory and multitasking makes walking and daily activities harder. Surgeons will implant deep brain stimulation electrodes in both the subthalamic nucleus to control motor symptoms and the nucleus basalis of Meynert to stimulate cholinergic pathways; NBM stimulation aims to boost cortical acetylcholine to improve attention, executive function and dual-task walking. The stimulator is used alongside usual Parkinson's medications, and you may be asked to temporarily stop meds for certain research visits so researchers can measure effects clearly. The trial is looking for people ages 21 to 80 with Parkinson's who are approved or planning for STN DBS, can give consent and pause meds for visits, and who do not have dementia, uncontrolled psychiatric illness, a seizure history, pregnancy, or need an assistive device to walk 100 feet.
Locations
- Stanford Neuroscience Health Center, Stanford, California, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Combined STN+NBM DBS. The goal is to treat the cognitive-motor syndrome in Parkinson's, where trouble with attention, memory and multitasking makes walking and daily activities harder. Surgeons will implant deep brain stimulation electrodes in both the subthalamic nucleus to control motor symptoms and the nucleus basalis of Meynert to stimulate cholinergic pathways; NBM stimulation aims to boost cortical acetylcholine to improve attention, executive function and dual-task walking. The stimulator is used alongside usual Parkinson's medications, and you may be asked to temporarily stop meds for certain research visits so researchers can measure effects clearly. The trial is looking for people ages 21 to 80 with Parkinson's who are approved or planning for STN DBS, can give consent and pause meds for visits, and who do not have dementia, uncontrolled psychiatric illness, a seizure history, pregnancy, or need an assistive device to walk 100 feet.
- Who can participate?
- Participants must be between 21 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 10 months.